PT - JOURNAL ARTICLE AU - Sjoerd Euser AU - Sem Aronson AU - Irene Manders AU - Steven van Lelyveld AU - Bjorn Herpers AU - Jan Sinnige AU - Jayant Kalpoe AU - Claudia van Gemeren AU - Dominic Snijders AU - Ruud Jansen AU - Sophie Schuurmans Stekhoven AU - Marlies van Houten AU - Ivar Lede AU - James Cohen Stuart AU - Fred Slijkerman Megelink AU - Erik Kapteijns AU - Jeroen den Boer AU - Elisabeth Sanders AU - Alex Wagemakers AU - Dennis Souverein TI - SARS-CoV-2 viral load distribution reveals that viral loads increase with age: a retrospective cross-sectional cohort study AID - 10.1101/2021.01.15.21249691 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.15.21249691 4099 - http://medrxiv.org/content/early/2021/01/22/2021.01.15.21249691.short 4100 - http://medrxiv.org/content/early/2021/01/22/2021.01.15.21249691.full AB - Objective To describe the SARS-CoV-2 viral load distribution in different patient groups and age categories.Methods All SARS-CoV-2 RT-PCR results from nasopharyngeal (NP) and oropharyngeal (OP) swabs (first PCR from unique patients only) that were collected between January 1 and December 1, 2020, predominantly in the Public Health Services regions Kennemerland and Hollands Noorden, province of North Holland, the Netherlands were included in this study. Swabs were derived from patients with respiratory symptoms who were presented at the general practitioner (GP), hospital, or hospital health care workers (HCWs) of four regional hospitals, nursing home residents and HCWs of multiple nursing homes, and in majority (>75%) from Public Health testing facilities of the two Public Health Services. SARS-CoV-2 PCR crossing point (Cp) values were used to estimate viral loads (higher Cp-values indicate lower viral loads).Results In total, 278.455 unique patients were tested of whom 9·1% (n=25.374) were SARS-CoV-2 positive. As there were differences in viral load distribution between tested populations, further analyses focused on PCRs performed by public health services (n=211.914) where sampling and inclusion were uniform. These data reveal a clear relation between age and SARS-CoV-2 viral load, with especially children aged<12 years showing lower viral loads than shown in adults (β: −0·03, 95CI% −0·03 to −0·02, p<0·001), independent of sex and/or symptom duration. Interestingly, the median Cp-values between the oldest (>79 years) and youngest (<12 years) population differed by over 4 PCR cycles, suggesting approximately a 16-fold difference in viral load. In addition, the proportion of children aged <12 years with a low load (Cp-value >30) was significantly higher compared to the other patients (31·1% vs. 17·2%, p-value<0.001).Conclusion We observed that in patients tested by Public Health Services, SARS-CoV2 viral load increases significantly with age. Previous studies suggest that young children (<12 years) play a limited role in SARS-CoV-2 transmission. Currently, the relation between viral load and infectivity is not yet well understood, and further studies should elucidate whether the lower viral load in children is indeed related to their suggested limited role in SARS-CoV-2 transmission. Moreover, as rapid antigen tests are less sensitive than PCR, these results suggest that SARS-CoV-2 antigen tests could have lower sensitivity in children than in adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no external funding received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethical Committee of the Amsterdam UMC approved this study on January 19th, 2021 (Study number: 2021.0022). In addition, the Institutional Review Board of the Spaarne Gasthuis, Hoofddorp/Haarlem, the Netherlands, approved to conduct the study on November 10th, 2020 (Study number: 2020.0154). The data were anonymized after collection and analyzed under code.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request